About Servier

Servier develops targeted therapies in oncology, cardiometabolism, and rare neurological disorders. Founded in 1954 and governed by a non profit foundation, the company operates independently, reinvesting close to 20% of revenue into research. With over 20,000 employees, Servier collaborates with academic researchers, biotech firms, and patient communities to address unmet medical needs. The patient first approach shapes every development stage, from early research at the Paris Saclay Institute to commercialization in over 130 countries. Strategic acquisitions in rare oncology and the launch of Servier Ventures accelerate breakthrough innovation while maintaining the long term vision afforded by foundation governance.